StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Earnings

Aptevo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q3 FY2025
–
EPS, Q3 FY2025
-$2.23
-$0.48 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Aptevo Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 14, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 13, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close––-$2.23Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025before the open––-$8.40Release
Q1 FY2025ended Mar 31, 2025May 15, 2025after the close––-$4.39Release
Q4 FY2024ended Dec 31, 2024Feb 14, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open––-$0.48Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open––-$1.67Release
Q1 FY2024ended Mar 31, 2024May 8, 2024before the open––-$9.95Release
Q4 FY2023ended Dec 31, 2023Mar 5, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Aptevo Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Aptevo Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Aptevo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. News
  4. News
  5. News
  6. News
  7. News
  8. News
  9. News
  10. Results
  11. News
  12. News
  13. News
  14. Update
  15. Update

See a number that looks wrong?